Videos And Webinars

1. How NK Cell Therapies Are Poised For Breakthroughs In Cancer 10/1/2025

   In this first segment of our Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, expert panelists, Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, highlighted how natural killer (NK) cell therapies are showing promising results in cancer treatment with compelling patient improvements and safety. Ryan shared personal success stories, including her daughter's recovery, while Ognar noted robust research and the unique advantages of NK cells, especially their potential for scalable, off-the-shelf treatments that could broaden access and reduce costs.

2. Scaling Allogeneic NK Cell Therapies 10/1/2025

   In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, highlighted the allogeneic, off-the-shelf nature of their NK cell therapy. Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics expressed strong confidence that NK cell therapies can be produced at a fraction of the cost of autologous treatments, making them widely accessible and commercially viable.

3. Why Prolonged, Potent NK Cells May Transform Cancer Therapy 10/1/2025

   In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics explained that his team’s technology enables NK cells to remain active and highly cytotoxic for weeks. This innovation combines functional longevity and strategic targeting of the immunosuppressive tumor microenvironment, opening doors for more effective, safer cancer treatment.

4. Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation | Audience Q&A 10/1/2025

   In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, provided detailed responses to the audience questions about challenges in donor variability for allogeneic NK cell therapies, rigorous patient safety criteria focused on health status, cryopreservation, and more.

5. NK-Specific Strategies To Unlock Full Therapeutic Power 10/1/2025

   In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, expert panelists Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, emphasized that natural killer (NK) cells require distinct, tailored activation methods to unlock their full therapeutic potential in cancer. They argued that unfair comparisons with T cells hinder innovation and highlighted how NK-focused engineering boosts both persistence and cytotoxicity.

6. Rigorous Safety Monitoring Central To NK Cell Therapy Development 10/1/2025

   In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics. emphasized that safety is a key advantage of NK cell therapies over T cells, as NK cells have a lower risk of severe toxicities demonstrated in both preclinical models and patient treatments. She shared that her team integrates comprehensive safety monitoring into trial design to ensure patient well-being and regulatory confidence.

7. Next-Gen NK Cell Platforms Show Promise In Cancer, Immune Recovery 10/1/2025

   In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, expert panelists Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, share why cutting-edge NK cell therapies are advancing through proprietary activation technologies that allow longer, more potent anti-cancer responses and unique immune system repair.

8. Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation 9/18/2025

   As the cell therapy space evolves beyond T cells, allogeneic natural killer (NK) cell therapies are emerging as a scalable and accessible approach in cancer immunotherapy. Cell & Gene's Chief Editor, Erin Harris, welcomed experts Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics, and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, for a detailed discussion exploring how their teams are advancing the field through distinct yet complementary strategies. The dynamic discussion highlighted the scientific innovation, technological differentiation, and patient-centered vision driving the next generation of allogeneic NK cell therapies, and why now is the critical moment to deepen research and exploration into novel NK platforms.

9. Approaches To Implementing Automation In Cell Therapy Technology 12/14/2022

   Explore expert insights on the evolution of automation processes, designing or sourcing instruments to support your process, and regulatory compliant workflows.

10. Building The Complete Solution For Viral Vector Production 2/7/2022

    AAV is becoming the go-to biological delivery method for gene therapy breakthroughs. Learn how to scale and accelerate your viral vector production from research to commercialization.